A distinct inflammatory profile marked by neutrophil activity and cytokine elevation may underline poor biological response ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Mepolizumab treatment was associated with a modest improvement in FEV 1 (mean, 300 ml), a nonsignificant improvement in asthma symptoms, and a significant improvement in scores on the Juniper ...

With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe exacerbations in a year, according to results published in The New England ...

The phase 3 MATINEE trial (NCT04133909) provided additional context for where mepolizumab may be most useful. 2 This trial randomized 804 patients with a history of frequent exacerbations and ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in patients with COPD regardless of the history or severity of ...

Mepolizumab is currently being investigated for severe hypereosinophilic syndrome, nasal polyposis and COPD. In the US, Nucala (100mg fixed dose subcutaneous injection of mepolizumab ...

Mepolizumab, sold as Nucala, was not compared fairly against other asthma treatments, raising questions as to whether it has benefits over other drugs already used for the condition, ...

Mepolizumab is the only approved biologic evaluated in patients with an eosinophilic phenotype characterized by a blood eosinophil count (BEC) threshold as low as ≥150 cells/µL. 1,2 BEC is ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

Mepolizumab was found to significantly reduce exacerbations in adults with chronic obstructive pulmonary disease (COPD), according to results from the MATINEE trial.

The researchers found that the annualized rate of moderate or severe exacerbations was significantly lower with mepolizumab than placebo (0.80 vs 1.01 events per year; rate ratio, 0.79).